QLS1410 in Participants With Uncontrolled Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 260 participants.

Also called NCT07489612

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 260 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07489612
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT07489612. Randomized; quadruple masking; primary purpose treatment. Start 2026-04 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
QLS1410 in Participants With Uncontrolled Hypertension
Condition
Hypertension (HTN)
Intervention (Drug)
Dose 1 of QLS1410
Intervention (Drug)
Dose 2 of QLS1410
Intervention (Drug)
Dose 3 of QLS1410
Intervention (Drug)
placebo
Lead sponsor
Qilu Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07489612
Content hash
ce20064385d4b8947e381d5d4368b6401f61a3ee1f8eb3f973f154cadab25b18